文献速递核素与放射性配体治疗肿瘤 PET/CT

靶向GPC-1的177Lu标记Miltuximab®抗体用于前列腺癌的靶向β治疗

Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).
PubMed 文献 · EJNMMI Res · 2020-05-07

本研究在人前列腺癌DU-145小鼠异种移植模型中,评估了89Zr标记Miltuximab®的PET显像和177Lu标记Miltuximab®的靶向β治疗潜力。结果显示抗体在肿瘤中蓄积高于其他器官,6 MBq [177Lu]Lu-DOTA-Miltuximab®显著抑制肿瘤生长,10 MBq组平均生存85天 vs 对照45天,组织病理学未见相关异常。

要点

  • 89Zr标记Miltuximab®的PET-CT可检出DU-145异种移植瘤中抗体蓄积。
  • 6 MBq [177Lu]Lu-DOTA-Miltuximab®较对照DOTA-Miltuximab®显著抑制肿瘤生长。
  • 10 MBq组平均生存85天 vs 对照45天,组织病理学未见相关异常。

核心结论

  • 这些发现表明Miltuximab®作为PET显像剂([89Zr]Zr-DFO-Miltuximab®)和β治疗剂([177Lu]Lu-DOTA-Miltuximab®)在前列腺癌或其他GPC-1表达肿瘤患者中具有潜在用途。

研究设计与样本

  • 研究为在人前列腺癌DU-145小鼠异种移植模型中开展的临床前研究。
  • 雄性BALB/c裸鼠皮下接种GPC-1阳性DU-145前列腺癌细胞。
  • 显像与生物分布研究:荷瘤小鼠接受2.62 MBq [89Zr]Zr-DFO-Miltuximab®后行PET-CT显像,或接受6 MBq [177Lu]Lu-DOTA-Miltuximab®行切伦科夫显像及离体生物分布评估。
  • 初始疗效研究:荷瘤小鼠静脉给予6 MBq [177Lu]Lu-DOTA-Miltuximab®或对照DOTA-Miltuximab®,27天后处死。
  • 生存疗效研究:荷瘤小鼠给予3或10 MBq [177Lu]Lu-DOTA-Miltuximab®或对照,随访至120天。

主要发现

  • PET-CT显像使用[89Zr]Zr-DFO-Miltuximab®可检出DU-145异种移植瘤中抗体蓄积,注射[177Lu]Lu-DOTA-Miltuximab®后的切伦科夫发光显像予以确认。
  • 多个时间点肿瘤中抗体蓄积(% IA/g)高于其他器官。
  • 单次注射6 MBq [177Lu]Lu-DOTA-Miltuximab®较DOTA-Miltuximab®(对照)显著抑制肿瘤生长。
  • 生存研究中,10 MBq [177Lu]Lu-DOTA-Miltuximab®组平均生存85天 vs 对照45天,生存显著延长,该效应与癌细胞凋亡增加相关。
  • 组织病理学评估显示未见与[177Lu]Lu-DOTA-Miltuximab®相关的异常,与其他耐受性观察(包括体重稳定)一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate cancer (PCa). This study investigated the potential of 89Zr-labelled Miltuximab® as an imaging agent, and 177Lu-labelled Miltuximab® as a targeted beta therapy, in a mouse xenograft model of human prostate cancer. METHODS: Male BALB/c nude mice were inoculated subcutaneously with GPC-1-positive DU-145 PCa cells. In imaging and biodistribution studies, mice bearing palpable tumours received (a) 2.62 MBq [89Zr]Zr-DFO-Miltuximab® followed by PET-CT imaging, or (b) 6 MBq [177Lu]Lu-DOTA-Miltuximab® by Cerenkov imaging, and ex vivo assessment of biodistribution. In an initial tumour efficacy study, mice bearing DU-145 tumours were administered intravenously with 6 MBq [177Lu]Lu-DOTA-Miltuximab® or control DOTA-Miltuximab® then euthanised after 27 days. In a subsequent survival efficacy study, tumour-bearing mice were given 3 or 10 MBq of [177Lu]Lu-DOTA-Miltuximab®, or control, and followed up to 120 days. RESULTS: Antibody accumulation in DU-145 xenografts was detected by PET-CT imaging using [89Zr]Zr-DFO-Miltuximab® and confirmed by Cerenkov luminescence imaging post injection of [177Lu]Lu-DOTA-Miltuximab®. Antibody accumulation was higher (% IA/g) in tumours than other organs across multiple time points. A single injection with 6 MBq of [177Lu]Lu-DOTA-Miltuximab® significantly inhibited tumour growth as compared with DOTA-Miltuximab® (control). In the survival study, mice treated with 10 MBq [177Lu]Lu-DOTA-Miltuximab® had significantly prolonged survival (mean 85 days) versus control (45 days), an effect associated with increased cancer cell apoptosis. Tissue histopathology assessment showed no abnormalities associated with [177Lu]Lu-DOTA-Miltuximab®, in line with other observations of tolerability, including body weight stability. CONCLUSION: These findings demonstrate the potential utility of Miltuximab® as a PET imaging agent ([89Zr]Zr-DFO-Miltuximab®) and a beta therapy ([177Lu]Lu-DOTA-Miltuximab®) in patients with PCa or other GPC-1 expressing tumours.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Yeh MC, Tse BWC, Fletcher NL, et al. Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1). EJNMMI Res. 2020. PMID: 32382920. doi:10.1186/s13550-020-00637-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。